Liver fibrosis in patients with non-alcoholic fatty liver disease: Diagnostic options in clinical practice

Expert Opinion on Medical Diagnostics

Volumn 6, Issue 5, 2012, Pages 381-394

  Boursier, Jérôme ^a,b   Rousselet, Marie Christine ^a,b   Aubé, Christophe ^a,b   Calès, Paul ^a,b  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b LUNAM University   (France)

Author keywords

diagnosis; elasticity; fatty liver; fibrosis; hematologic tests; liver cirrhosis; non alcoholic fatty liver disease

Indexed keywords

ACOUSTIC RADIATION FORCE IMPULSE IMAGING; BLOOD ANALYSIS; BLOOD FIBROSIS TEST; CLINICAL EXAMINATION; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; ELASTOGRAPHY; HUMAN; INTERMETHOD COMPARISON; LIVER BIOPSY; LIVER FIBROSIS; LIVER INJURY; NONALCOHOLIC FATTY LIVER; REVIEW; ULTRASOUND SCANNER;

EID: 84865527100     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2012.691878     Document Type: Review

References (111)

1. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011;9(6):524-30
2. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008;28(4):339-50
3. Ertle J, Dechene A, Sowa JP, et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2010;128:2436-43
4. Dam-Larsen S, Franzmann M, Andersen IB, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004;53:750-5
5. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44(4):865-73
6. Soderberg C, Stal P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010;51(2):595-602
7. Angulo P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance? Hepatology 2010;51(2):373-5
8. Musso G, Gambino R, Cassader M, et al. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011;43(8):617-49
9. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/ NASH based on the EASL 2009 special conference. J Hepatol 2010;53(2):372-84
10. Alisi A, Locatelli M, Nobili V. Nonalcoholic fatty liver disease in children. Curr Opin Clin Nutr Metab Care 2010;13(4):397-402
11. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41(6):1313-21
12. Sanyal AJ, Brunt EM, Kleiner DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011;54(1):344-53
13. Younossi ZM, Stepanova M, Rafiq N, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011;53(6):1874-82
14. Castera L, Negre I, Samii K, et al. Pain experienced during percutaneous liver biopsy. Hepatology 1999;30(6):1529-30
15. Poynard T, Lebrec D. The inconvenience of investigations used in hepatology: patients' and hepatologists' opinions. Liver 1982;2(4):369-75
16. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344(7):495-500
17. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38(6):1449-57
18. Merriman RB, Ferrell LD, Patti MG, et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006;44(4):874-80
19. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128(7):1898-906
20. Vuppalanchi R, Unalp A, Natta ML, et al. Effects of liver biopsy sample length and number of readings on histologic yield for nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009;7(4):481-6
21. Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol 2009;50(1):1-3
22. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008;48(Suppl 1):S104-12
23. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003;29(12):1705-13
24. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94(9):2467-74
25. Poynard T, Halfon P, Castera L, et al. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem 2007;53(9):1615-22
26. Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010;51(2):454-62
27. Boursier J, Cales P. Clinical interpretation of Fibroscan(R) results: a real challenge. Liver Int 2010;30(10):1400-2
28. Arena U, Vizzutti F, Corti G, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 2008;47(2):380-4
29. Sagir A, Erhardt A, Schmitt M, et al. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology 2008;47(2):592-5
30. Coco B, Oliveri F, Maina AM, et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 2007;14(5):360-9
31. Millonig G, Reimann FM, Friedrich S, et al. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology 2008;48(5):1718-23
32. Yashima Y, Tsujino T, Masuzaki R, et al. Increased liver elasticity in patients with biliary obstruction. J Gastroenterol 2011;46(1):86-91
33. Millonig G, Friedrich S, Adolf S, et al. Liver stiffness is directly influenced by central venous pressure. J Hepatol 2010;52(2):206-10
34. Mederacke I, Wursthorn K, Kirschner J, et al. Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. Liver Int 2009;29(10):1500-6
35. Lupsor M, Badea R, Stefanescu H, et al. Analysis of histopathological changes that influence liver stiffness in chronic hepatitis C. Results from a cohort of 324 patients. J Gastrointestin Liver Dis 2008;17(2):155-63
36. Ziol M, Kettaneh A, Ganne-Carrie N, et al. Relationships between fibrosis amounts assessed by morphometry and liver stiffness measurements in chronic hepatitis or steatohepatitis. Eur J Gastroenterol Hepatol 2009; 21(11):1261-8
37. Sanchez-Conde M, Montes Ramirez ML, Bellon Cano JM, et al. Impact of liver steatosis on the correlation between liver stiffness and fibrosis measured by transient elastography in patients coinfected with human immunodeficiency virus and hepatitis C virus. J Viral Hepat 2011;18(7):e278-83
38. Arena U, Vizzutti F, Abraldes JG, et al. Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C. Gut 2008; 57(9):1288-93
39. Kim SU, Kim do Y, Ahn SH, et al. The impact of steatosis on liver stiffness measurement in patients with chronic hepatitis B. Hepatogastroenterology 2010;57(101):832-8
40. Yoneda M, Yoneda M, Mawatari H, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008;40(5):371-8
41. Lupsor M, Badea R, Stefanescu H, et al. Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis. J Gastrointestin Liver Dis 2010;19(1):53-60
42. Petta S, Di Marco V, Camma C, et al. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. Aliment Pharmacol Ther 2011;33(12):1350-60
43. Rousselet MC, Michalak S, Dupre F, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005;41(2):257-64
44. Germani G, Hytiroglou P, Fotiadu A, et al. Assessment of fibrosis and cirrhosis in liver biopsies: an update. Semin Liver Dis 2011;31(1):82-90
45. Boursier J, de Ledinghen V, Zarski JP, et al. Evaluation of liver lesions influencing Fibroscan results by new morphometric measurements: mainly but not only liver fibrosis. Hepatology 2010;52(Suppl 1):1130A
46. Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010;36(11):1825-35
47. Sasso M, Tengher-Barna I, Ziol M, et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan: validation in chronic hepatitis C. J Viral Hepatol 2012; In press
48. Castera L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010;51(3):828-35
49. Bossuyt PM, Reitsma JB, Bruns DE, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 2003;49(1):7-18
50. Friedrich-Rust M, Romen D, Vermehren J, et al. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. Eur J Radiol 2011; In press
51. Myers RP, Pomier-Layrargues G, Kirsch R, et al. Feasibility and diagnostic performance of the Fibroscan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012;2012(55):199-208
52. de Ledinghen V, Wong VW, Vergniol J, et al. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan. J Hepatol 2011; In press
53. Palmeri ML, Wang MH, Dahl JJ, et al. Quantifying hepatic shear modulus in vivo using acoustic radiation force. Ultrasound Med Biol 2008;34(4):546-58
54. Palmeri ML, Wang MH, Rouze NC, et al. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol 2011;55:666-72
55. Yoneda M, Imajo K, Kirikoshi H, et al. Acoustic radiation force-based shear stiffness and non-invasive panels of tests in Japanese patients with nonalcoholic fattly liver disease. J Hepatol 2011; In press
56. Friedrich-Rust M, Wunder K, Kriener S, et al. Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology 2009;252(2):595-604
57. Sporea I, Sirli RL, Deleanu A, et al. Acoustic radiation force impulse elastography as compared to transient elastography and liver biopsy in patients with chronic hepatopathies. Ultraschall Med 2011;32(Suppl 1):S46-52
58. Ebinuma H, Saito H, Komuta M, et al. Evaluation of liver fibrosis by transient elastography using acoustic radiation force impulse: comparison with Fibroscan((R)). J Gastroenterol 2011;46(10):1238-48
59. Colombo S, Buonocore M, Del Poggio A, et al. Head-to-head comparison of transient elastography (TE), real-time tissue elastography (RTE), and acoustic radiation force impulse (ARFI) imaging in the diagnosis of liver fibrosis. J Gastroenterol 2012; In press
60. Boursier J, Isselin G, Fouchard-Hubert I, et al. Acoustic Radiation Force Impulse: a new ultrasonographic technology for the widespread noninvasive diagnosis of liver fibrosis. Eur J Gastroenterol Hepatol 2009; 22(9):1074-84
61. Yin M, Talwalkar JA, Glaser KJ, et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007;5(10):1207-13; e2
62. Huwart L, Sempoux C, Vicaut E, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 2008;135(1):32-40
63. Muller M, Gennisson JL, Deffieux T, et al. Quantitative viscoelasticity mapping of human liver using supersonic shear imaging: preliminary in vivo feasibility study. Ultrasound Med Biol 2009;35(2):219-29
64. Bavu E, Gennisson JL, Mallet V, et al. Supersonic shear imagning is a new potent morphological non-invasive technique to assess liver fibrosis. Part II: comparison with Fibroscan. J Hepatol 2010;52(Suppl 1):S166
65. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steato-hepatitis. Aliment Pharmacol Ther 2011;33(5):525-40
66. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38(2):518-26
67. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43(6):1317-25
68. Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57(10):1441-7
69. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45(4):846-54
70. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357(9262):1069-75
71. Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005;51(10):1867-73
72. Cales P, Oberti F, Michalak S, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005;42(6):1373-81
73. Cales P, Laine F, Boursier J, et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 2009;50(1):165-73
74. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127(6):1704-13
75. Cales P, de Ledinghen V, Halfon P, et al. Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int 2008;28(10):1352-62
76. Adams LA, George J, Bugianesi E, et al. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2011;26(10):1536-43
77. Cales P, Veillon P, Konate A, et al. Reproducibility of blood tests of liver fibrosis in clinical practice. Clin Biochem 2008;41(1-2):10-18
78. Boursier J, Konate A, Gorea G, et al. Reproducibility of liver stiffness measurement by ultrasonographic elastometry. Clin Gastroenterol Hepatol 2008;6(11):1263-9
79. Yilmaz Y. Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease. Aliment Pharmacol Ther 2009;30(11-12):1103-9
80. Wieckowska A, Zein NN, Yerian LM, et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006;44(1):27-33
81. Feldstein AE, Wieckowska A, Lopez AR, et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009;50(4):1072-8
82. Miller MH, Ferguson MA, Dillon JF. Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease. Liver Int 2011;31(4):461-73
83. Mato JM, Lu SC. Where are we in the search for noninvasive nonalcoholic steatohepatitis biomarkers? Hepatology 2011;54(4):1115-17
84. Castera L, Sebastiani G, Le Bail B, et al. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010;52(2):191-8
85. Boursier J, de Ledinghen V, Zarski JP, et al. Comparison of 8 diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely non-invasive. Hepatology 2012;55(1):58-67
86. Boursier J, Bacq Y, Halfon P, et al. Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol 2009;21:28-38
87. Boursier J, Cales P. Combination of fibrosis tests: sequential or synchronous? Hepatology 2009;50(2):656-7
88. Boursier J, Vergniol J, Sawadogo A, et al. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis. Liver Int 2009;29(10):1507-15
89. Cales P, Boursier J, de Ledinghen V, et al. Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests. Gastroenterol Clin Biol 2008;32(12):1050-60
90. Boursier J, De Ledinghen V, Zarski J, et al. A new combination of blood test and Fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol 2011;106(7):1255-63
91. Forestier J, Dumortier J, Guillaud O, et al. Noninvasive diagnosis and prognosis of liver cirrhosis: a comparison of biological scores, elastometry, and metabolic liver function tests. Eur J Gastroenterol Hepatol 2010;22(5):532-40
92. Robic MA, Procopet B, Metivier S, et al. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. J Hepatol 2011;55(5):1017-24
93. Boursier J, Brochard C, Salvadori N, et al. Blood fibrosis tests are more accurate than liver biopsy for the prediction of death or cirrhosis complications in patients with chronic hepatitis C. Hepatology 2011;54(Suppl 1):1269A
94. Parkes J, Roderick P, Harris S, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010;59(9):1245-51
95. Jung KS, Kim SU, Ahn SH, et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology 2011;53(3):885-94
96. Masuzaki R, Tateishi R, Yoshida H, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 2009;49(6):1954-61
97. Vergniol J, Foucher J, Terrebonne E, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011;140(7):1970-9
98. Boursier J, Bertrais S, Marsault P, et al. Prediction of mortality by Fibroscan, FibroMeter and their combination in a cohort of 3,623 patients with chronic liver disease. Hepatology 2011;54(Suppl 1):1227A
99. Azagury DE, Lautz DB. Obesity overview: epidemiology, health and financial impact, and guidelines for qualification for surgical therapy. Gastrointest Endosc Clin N Am 2011;21(2):189-201
100. Nobili V, Vizzutti F, Arena U, et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008;48(2):442-8
101. Gaia S, Carenzi S, Barilli AL, et al. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J Hepatol 2011;54(1):64-71
102. Wong VW, Wong GL, Chim AM, et al. Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am J Gastroenterol 2008;103(7):1682-8
103. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008;47(2):455-60
104. Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009;7(10):1104-12
105. Fujii H, Enomoto M, Fukushima W, et al. Applicability of BARD score to Japanese patients with NAFLD. Gut 2009;58(11):1566-7
106. McPherson S, Stewart SF, Henderson E, et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010;59(9):1265-9
107. Ruffillo G, Fassio E, Alvarez E, et al. Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. J Hepatol 2011;54(1):160-3
108. Raszeja-Wyszomirska J, Szymanik B, Lawniczak M, et al. Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol 2010;10:67
109. Ratziu V, Massard J, Charlotte F, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006;6:6
110. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24(2):289-93
111. Lassailly G, Caiazzo R, Hollebecque A, et al. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity. Eur J Gastroenterol Hepatol 2011;23(6):499-506